Clinical Trial Update: Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of Sandostatin LAR Depot in patients with primary insulin hypersecretion and obesity has completed. No results are provided in the summ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insulin Hypersecretion
• Obesity

Drugs mentioned

• SANDOSTATIN LAR DEPOT (OCTREOTIDE ACETATE)

Snippet

Sponsor: Novartis | Conditions: Primary Insulin Hypersecretion, Obesity | Phase 2 | Status: COMPLETED